MS RESEARCH AUSTRALIA BRAIN BANK NEWS
Mayzent (siponimod) the first MS medication approved for secondary progessive MS in Australia, has been listed on the Pharmaceutical Benefits Scheme (PBS).
Two MS Research Australia funded research groups are investigating the role of messenger molecules and uncovering how genes increase the risk of ms.
New research from the International Progressive MS Alliance discovers a way nerve fibres protect themselves from damage.
Three MS treatments will be considered for inclusion on the PBS at a PBAC meeting in March – nabiximols (Sativex), siponimod (Mayzent), ozanimod (Zeposia).
MS Research Australia has funded six new MS studies totalling almost $150,000 in the first round of incubator […]
Associate Professor Kaylene Young and Professor Bruce Taylor are working towards new discoveries that may provide treatments to […]